Preparation and Evaluation of Bendamustine Hydrochloride Aqueous Formulations

Author(s)

Prasanna, S., Puranik, S. B.

Author's Affiliation

Abstract

B-cell chronic lymphocytic leukemia (B-CLL), also known as chronic lymphoid leukemia (CLL), is the most common type of leukemia. Leukemias are cancers of the white blood cells (leukocytes). CLL affects B cell lymphocytes. B cells originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. Bendamustine (INN, trade names Ribomustin and Treanda; also known as SDX-105) is a nitrogen mustard used in the treatment of chronic lymphocytic leukemias (CLL) and lymphomas. It belongs to the family of drugs called alkylating agents. It is also being studied for the treatment of sarcoma¹. Bendamustine Hydrochloride is commercially available in the market as lyophilizzed dosage form. Also enough literature is available that Bendamustine Hydrochloride is very unstable in the liquid dosage form. It undergoes hydrolytic degradation in the presence of water². Hence an attempt for developing a simple, aqueous and non aqueous based Bendamustine Hydrochloride formulations have been attempted.

Keywords

Bendamsutine Hydrochloride, Hydroxypropyl beta cyclodextrin, Mannitol

Cite This Article

Prasanna, S., Puranik, S. B. (2013). Preparation and Evaluation of Bendamustine Hydrochloride Aqueous Formulations. International Journal for Pharmaceutical Research Scholars (IJPRS), 2(2), 110-113.